Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Principal Investigator
Name
Jian-Lun Xu
Institution
NCI, DCP, BRG
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2006-0043
Initial CDAS Request Approval
Jul 1, 2006
Title
CA-125 Velocity
Summary
Biomarker such as CA125 usually provides an inexpensive noninvasive approach to cancer screening. The low background levels in healthy people are usually stable over time, while biomarker levels in patients with asymptomatic disease can behave differentially. Changes in a biomarker over time have been recognized as providing additional information, but only ad hoc. Rules have been suggested for measuring this information and incorporating it into the strategy. This study will model changes of biomarker over time and use the new model to predict the probability of having ovarian cancer.
Aims

Specific aims of the proposal are (i) to introduce a new model for the changes of biomarker over time which will generalize the available models, (ii) to use the new model to predict the probability of having ovarian cancer, and (iii) to apply the new model to ovarian cancer as well as prostate cancer in PLCO trial.

Related Publications